Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Salvatore Grisanti, Deborah Cosentini, Marta Laganà, Alessandra Morandi, Barbara Lazzari, Laura Ferrari, Alberto Dalla Volta, Roberta Ambrosini, Vittorio Domenico Ferrari, Sandra Sigala, Alfredo Berruti
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-02-01
Edice:	Frontiers in Endocrinology
Témata:	adrenocortical carcinoma gemcitabine capecitabine prognostic factor chemotherapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fendo.2021.624102/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!